logo
Plus   Neg
Share
Email

Lorus Therapeutics Q3 Loss Narrows - Quick Facts

Canadian biopharmaceutical company Lorus Therapeutics Inc. (LOR.TO,LRUSF.PK) posted a narrower loss in the third quarter.

The company posted third-quarter net loss of C$1.0 million or C$0.05per share, narrower than than C$1.5 million or C$0.10 per share last year. Lorus Therapeutics attributed the wider net loss mainly to higher general and administrative, and research and development expenditures.

The company did not generate any revenues in both the quarters.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Each year, more than eight million children die from preventable diseases in countries with the worst health care systems . Kofi Annan, former head of the UN, said that, "Almost all these deaths will happen in developing countries. A large number of them could be prevented." You do not want to find... As Canada prepares to legalize marijuana nationwide later this year, a national survey by Statistics Canada has thrown up some interesting facts - including that legal marijuana is not a temptation for most Canadians. Regardless of cannabis use, 79 percent of Canadians surveyed said they would not be more likely to try or increase their cannabis consumption just because it is legalized. The Procter & Gamble Company (PG) reported third-quarter net earnings per share of $0.95, an increase of two percent versus the prior year. Net earnings from continuing operations declined 1% year-over-year to $2.54 billion. Core earnings per share increased four percent to $1.00. On average, 20 analysts...
Follow RTT